Heterocyclic Compounds

Matches 1 - 50 out of 34,050	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/088189A1	MACROCYCLIC COMPOUND AS CDK9 INHIBITOR AND USE THEREOF The present disclosure provides a compound of formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.
WO/2024/088237A1	LUMINESCENT MATERIAL, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE CONTAINING SAME Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
WO/2024/088311A1	CRYSTAL FORM OF IMIDAZOPYRAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention belongs to the technical field of medicine, and specifically relates to a crystal form of an imidazopyrazine derivative represented by formula (I), a preparation method therefor and a use thereof.
WO/2024/089008A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/088183A1	ANTICORONVIRAL COMPOUNDS AND COMPOSITIONS AND USES THEREOF Provided herein are compounds which exhibit activity in the inhibition of RNA polymerase as well as pharmaceutical compositions comprising these compounds and methods of treatment of viral infections by administration of these compounds ...
WO/2024/088922A1	HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL) The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, W, Y, Z, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
WO/2024/088069A1	PREPARATION FOR AROMATIC KRAS MUTANT PROTEIN INHIBITOR AND USE THEREOF Compounds of general formula (I) and formula (II) have good activity for inhibiting tumor growth and have good safety. Provided are preparation for a Kras inhibitor and a use thereof. Specifically, provided are compounds represented by f...
WO/2024/091498A1	COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Disclosed are compounds that are parathyroid hormone receptor 1 agonists, and methods useful for preventing or treating osteoporosis, fracture, osteomalacia, arthritis, thrombocytopenia, hypoparathyroidism, hyperphosphatemia or tumoral c...
WO/2024/088343A1	ARYL HETEROCYCLIC KV1.3 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF A novel Kv1.3 channel (or KV1.3) inhibitor, which can be used for preventing and/or treating diseases related to the Kv1.3 channel (or Kv1.3), including immune and inflammatory diseases, such as: multiple sclerosis, inflammatory bowel di...
WO/2024/088408A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound, a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. Provided is a compound as shown in formula (I) or a pharmaceutically acceptable sal...
WO/2024/092222A1	MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR D AND RELATED PRODUCTS AND METHODS Methods are provided for modulating MRGPRD generally, or for treating a MRGPRD dependent condition more specifically, by contacting the MRGPRD or administering to a subject in need thereof, respectively, an effective amount of a compound...
WO/2024/091473A1	TRIAZOLOPYRIDAZINE COMPOUNDS USEFUL AS RAC1 INHIBITORS Disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, carrier or diluent and a compound of Formula I: or a pharmaceutically acceptable salt thereof. The variables are defined herein. Also disclosed...
WO/2024/089191A1	MICROBIOCIDAL HETEROBICYCLIC DIHYDROOXADIAZINE DERIVATIVES A compound of Formula (I) wherein Qa or Qb is N, the other is C, Qc is N or CH, one or two of Q7, Q8, and Q9 are N, the other or the others being CR7, CR8 and CR9 respectively, and the other substituents are as defined in claim 1, useful...
WO/2024/064701A3	ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
WO/2024/090469A1	FUSED PYRIDAZINE DERIVATIVE The present invention addresses the problem of providing a pharmaceutical composition, particularly a compound that is suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases.　The inventors of th...
WO/2024/088409A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR, AND THE USE THEREOF Disclosed in the present invention are nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof, a preparation method therefor, and the use thereof. Provided in the present invention are compounds represen...
WO/2024/091370A1	5,6-FUSED BICYCLIC HETEROAROMATIC COMPOUNDS The present invention provides 5,6-bicyclic heteroaromatic compounds, particularly a compound of formula (I) and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula (I) in treating d...
WO/2024/088377A1	PYRIMIDOPYRROLE ANALOG Disclosed are a compound as represented by general formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, X and Y are as defined in the present disclosure.
WO/2024/046471A9	USP1 INHIBITOR The present application provides a class of novel compounds having a USP1 inhibitory activity as shown in formula (II'), pharmaceutical compositions comprising the compounds, useful intermediates for preparing the compounds, and a method...
WO/2024/089006A1	HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING The present invention relates to compounds of formula (I) which are capable of activating STING (Stimulator of Interferon Genes). The present invention further relates to pharmaceutical compositions comprising at least a compound of form...
WO/2024/088184A1	ANTI-FELINE-CORONAVIRUS COMPOUNDS AND USES THEREOF Provided herein are compounds which exhibit antiviral activity against feline coronavirus and methods of treatment of feline coronavirus infections by administration of these compounds or the pharmaceutical compositions comprising the same.
WO/2024/084496A1	PHARMACEUTICAL COMPOSITIONS COMPRISING ACALABRUTINIB MALEATE The present invention relates to pharmaceutical compositions comprising a Bruton tyrosine kinase (BTK) inhibitor. More particularly, the present invention relates to a composition comprising Acalabrutinib maleate and one or more pharmace...
WO/2024/083024A1	PREPARATION AND USE OF RET INHIBITOR Disclosed in the present invention are preparation and a use of a c-RET inhibitor. Specifically, the present invention provides a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, a pharmaceutical com...
WO/2024/084217A1	3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
WO/2024/086296A1	COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
WO/2024/084450A1	BICYCLIC HETEROARYL COMPOUNDS AND THEIR DERIVATIVES AS PKMYT1 INHIBITORS The present disclosure provides bicyclic heteroaryl compounds and their derivatives of formula (I), which are therapeutically useful as PKMYT1 inhibitors. (I) These compounds are useful in the treatment and/or prevention of diseases or c...
WO/2024/083773A1	TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS The present invention relates to compounds, compositions containing them, and to their use in the treatment of various disorders, in particular autoimmune, autoinflammatory or immune-mediated conditions, such as systemic lupus erythemato...
WO/2024/084448A2	FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Compounds of formula (I) and a pharmaceutically acceptable salt thereof, wherein ring A, W, X, Y, L1, R1, R3, and R4, are as defined in the specification, are useful for treating or preventing cancer or an immune-related disease or condi...
WO/2024/086179A1	PYRIMIDINE SGC STIMULATORS The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more ...
WO/2024/083150A1	CRYSTAL FORM OF NK3R ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention are a crystal form A of the NK3R antagonist represented by formula (I), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form A comprises charac...
WO/2024/086837A1	METHODS OF SYNTHESIS FOR CUCURBITURIL COMPOUNDS Disclosure herein relates to, inter alia, inventive cucurbituril compounds and novel methods of preparing thereof using a glycoluril compound having the formula (II), a glycoluril compound having the formula (II'), a glycoluril bis-ether...
WO/2024/086361A1	MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF Described herein are molecular glue degrader compounds that bind to both a target protein and a RING E3 Ubiquitin Ligase, as well as related compositions and methods of use, e.g., for degradation of the target protein and/or the treatmen...
WO/2024/083223A1	MACROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
WO/2024/083246A1	KRAS INHIBITORS The present disclosure relates to compounds that inhibit KRAS. In particular, the present disclosure relates to compounds that inhibit the activity of KRAS G12D or KRAS G12V, pharmaceutical compositions comprising the compounds and metho...
WO/2024/078436A1	HETEROCYCLIC PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF The present disclosure discloses a compound having formula (I) or a pharmaceutically acceptable salt thereof which acts as a USP1 inhibitor, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt the...
WO/2024/079351A1	NOVEL PIPERAZINE-BASED SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
WO/2024/078263A1	PREPARATION AND USE OF MACROCYCLIC HETEROCYCLIC COMPOUND AS EGFR INHIBITOR The present invention relates to a macrocyclic heterocyclic compound as a selective inhibitor of a clinical mutant of EGFR kinase, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt ther...
WO/2024/078370A1	SMALL MOLECULAR COMPOUND HAVING SUBSTITUTED PHENYLSPIRO[INDOLINE-3,3'-PYRROLIDINE] STRUCTURE Disclosed in the present invention is a small molecular compound having a substituted phenylspiro[indoline-3,3'-pyrrolidine] structure. The structure thereof is as shown in general formula I, and the definition of each substituent is as ...
WO/2024/078372A1	HETEROCYCLIC SUBSTITUTED PHENOL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a heterocyclic substituted phenol derivative, a preparation method therefor, and a use thereof. Specifically, provided are compounds of formulas (I-1), (II-1B), (III), and (IV), stereoisomers thereof, pharmaceutically accept...
WO/2024/081914A1	COELENTERAZINE ANALOGUES Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays. For example, the compounds may be u...
WO/2024/079682A1	SULFOXIMINE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
WO/2024/079342A1	COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1R) The present invention relates to new pyrrolopyrimidines and purines which surprisingly act as CSF-1R inhibitors, to processes for making these compounds, and to uses thereof.
WO/2024/078448A1	HPK1 KINASE INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Provided are an HPK1 kinase inhibitor, a preparation method therefor and the use thereof. The kinase inhibitor can adjust (for example, inhibit) HPK1 kinase activity, and thus can be used for treating various HPK1-related diseases includ...
WO/2024/078004A1	USE OF PEMETREXED NEAR-INFRARED FLUORESCENT MOLECULE TARGETING α-TYPE FOLATE RECEPTOR AS FLUORESCENT TRACER Disclosed is a use of a pemetrexed near-infrared fluorescent molecule targeting an α-type folate receptor as a fluorescent tracer, the structural formula of the pemetrexed near-infrared fluorescent molecule being: formula (I). The foreg...
WO/2024/081927A1	COMPOUNDS FOR IMPROVEMENT OF VIRAL PRODUCTION Provided herein are methods of improving (e.g., increasing) the production of viral particles (e.g., AAV) in mammalian cells (e.g., HEK293 or HEK293T cells) using selective HDAC6 inhibitors (e.g., compounds of Formula I, Formula II, or F...
WO/2024/078137A1	ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS An organic electroluminescent device and an electronic apparatus. The organic electroluminescent device comprises a cathode, an anode, and an organic layer, the organic layer comprises an organic light-emitting layer, and the organic lig...
WO/2024/079345A1	COMPOUND ACTIVE AS INHIBITOR OF COLONY STIMULATION FACTOR-1 RECEPTOR (CSF-1 R) The present invention relates to new pyrrolopyrimidines and purines which surprisingly act as CSF-1R inhibitors, to processes for making these compounds, and to uses thereof.
WO/2024/079623A1	TRICYCLIC COMPOUNDS AND THEIR USES The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses...
WO/2024/077273A2	COMPOUNDS, COMPOSITIONS, AND METHODS The present disclosure relates generally to small molecule inhibitors of Sterile Alpha and TIR Motif containing 1 (SARM1) protein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomer...
WO/2024/077235A2	DIHYDROFOLATE REDUCTASE INHIBITORS FOR ANTI-BIOTIC RESISTANT INFECTIONS In one aspect, compounds and associated compositions are described herein for the treatment of various bacterial infections, including antibiotic resistant infections. In some embodiments, an antibacterial composition described herein co...

Matches 1 - 50 out of 34,050	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >